Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 2. Infliximab treatment effect

Published byLauren Patrick Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 2. Infliximab treatment effect"— Presentation transcript:

1 Figure 2. Infliximab treatment effect
Infliximab treatment effect (A) Median EDSS-NBS scores of 15 patients calculated from a total of 123 clinical assessments are shown. Period corresponding to the time between median preinfliximab NBS duration (29.1 months, range 5.0–180.7 months) and the median follow-up time after infliximab initiation (39.0 months, range 16.0–104.9 months) are marked. The median EDSS-NBS scores start and continue to increase during the median preinfliximab NBS period, but clearly stabilize after the switch to infliximab. (B) Preimmunosuppression, postimmunosuppression preinfliximab, and postinfliximab disability accumulation rates for individual patients are shown. A positive disability accumulation rate indicates worsening disability. A zero value in disability accumulation rate indicates complete cessation of disability accumulation. A negative disability accumulation rate indicates improvement from enrollment disability level. EDSS-NBS = Expanded Disability Status Scale modified for neuro-Behçet syndrome. Burcu Zeydan et al. Neurol Neuroimmunol Neuroinflamm 2016;3:e258 © 2016 American Academy of Neurology

Download ppt "Figure 2. Infliximab treatment effect"

Similar presentations

Figure EDSS, FS scores, and Modified MSFC scores

Figure EDSS, FS scores, and Modified MSFC scores
Figure 2 ALSFRS-R changes (A) Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) slope after 6 months of treatment without (left)

Figure 2 ALSFRS-R changes (A) Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) slope after 6 months of treatment without (left)
Figure 1 The topographical model of multiple sclerosis, clinical (A) and subclinical (B) views The topographical model of multiple sclerosis, clinical.

Figure 1 The topographical model of multiple sclerosis, clinical (A) and subclinical (B) views The topographical model of multiple sclerosis, clinical.
Figure 3 Associations of [11C](R)-PK11195 binding to disability and diffusion tensor imaging (DTI) changes in patients with MS Associations of [11C](R)-PK11195.

Figure 3 Associations of [11C](R)-PK11195 binding to disability and diffusion tensor imaging (DTI) changes in patients with MS Associations of [11C](R)-PK11195.
Figure 2. Change in total PSPRS score from baseline to each study visit for all participants Change in total PSPRS score from baseline to each study visit.

Figure 2. Change in total PSPRS score from baseline to each study visit for all participants Change in total PSPRS score from baseline to each study visit.
Figure Brain MRI of the patient throughout the disease course(A) Brain MRI at the time of cerebral toxoplasmosis diagnosis (a) and after 1 month of toxoplasmosis.

Figure Brain MRI of the patient throughout the disease course(A) Brain MRI at the time of cerebral toxoplasmosis diagnosis (a) and after 1 month of toxoplasmosis.
Figure 1 Patient flow diagram

Figure 1 Patient flow diagram
Figure 3 Example of venous narrowing

Figure 3 Example of venous narrowing
Figure 3 JCV index changes in JCV+ patients

Figure 3 JCV index changes in JCV+ patients
Figure 2 FXTAS Rating Scale scores for case 1

Figure 2 FXTAS Rating Scale scores for case 1
Figure 1 ERG peak time delay at baseline

Figure 1 ERG peak time delay at baseline
Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.

Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.
Figure 1 Peripheral blood leukocyte subset counts during dimethyl fumarate treatmentComplete blood cell counts were obtained at baseline (n = 34) and at.

Figure 1 Peripheral blood leukocyte subset counts during dimethyl fumarate treatmentComplete blood cell counts were obtained at baseline (n = 34) and at.
Figure 2 Overview of the patient's history and immunofluorescence pattern of patient CSF IgG Overview of the patient's history and immunofluorescence pattern.

Figure 2 Overview of the patient's history and immunofluorescence pattern of patient CSF IgG Overview of the patient's history and immunofluorescence pattern.
Figure 1 Characteristics of the German National MS Cohort

Figure 1 Characteristics of the German National MS Cohort
Figure 3 Clinical outcome of apheresis therapies for NMOSD attacks

Figure 3 Clinical outcome of apheresis therapies for NMOSD attacks
Figure 2 JCV index JCV index (A) Fifty samples of natalizumab-treated patients with multiple sclerosis were assessed twice for their anti-JCV antibody.

Figure 2 JCV index JCV index (A) Fifty samples of natalizumab-treated patients with multiple sclerosis were assessed twice for their anti-JCV antibody.
Figure 3. Time curves for GFAP, S100B, and tTau release in CSF

Figure 3. Time curves for GFAP, S100B, and tTau release in CSF
Figure 2 Example of venous narrowing

Figure 2 Example of venous narrowing
Figure 1 Schematic overview of flow cytometry Schematic overview on the analysis of peripheral immune cells by flow cytometry. Schematic overview of flow.

Figure 1 Schematic overview of flow cytometry Schematic overview on the analysis of peripheral immune cells by flow cytometry. Schematic overview of flow.

Similar presentations

Ads by Google